Tuesday, 01 July 2025
This website uses cookies. By using our site you agree to our privacy policy
Username:
Password:
Lost username/password
Create an account
  • Home
  • About Us
    • Accreditation
    • Contact Us
  • Newsletters
  • Continuing Education
    • Diffuse Large B-cell Lymphoma
    • Follicular Lymphoma
    • CLL in Rural America
    • Multidisciplinary Perspectives on BTK Inhibitors Adverse Events Management in CLL and MCL

Stephen M. Ansell, MD, PhD

Professor, of Medicine
Mayo Clinic College of Medicine
Rochester, Minnesota
Last modified: November 26, 2018
Authored Items
What are today’s key issues and challenges in the management of front-line classical Hodgkin lymphoma?
Stephen M. Ansell, MD, PhD
FAQ published on December 8, 2017
Beyond current treatment options in frontline therapy, what future changes may lie ahead?
Stephen M. Ansell, MD, PhD
FAQ published on September 29, 2017
How does the safety and efficacy differ between the anti-PD-1 antibodies pembrolizumab & nivolumab?
Stephen M. Ansell, MD, PhD
FAQ published on July 24, 2017
What is the role of new and emerging checkpoint inhibitors in the treatment of classical HL?
Stephen M. Ansell, MD, PhD
FAQ published on June 19, 2017
What are our treatment options today in the post-ASCT setting in patients with classical HL?
Stephen M. Ansell, MD, PhD
FAQ published on June 7, 2017
Newly Diagnosed, Early Stage HL: Treatment Strategies for Improving Long-term Outcomes
Stephen M. Ansell, MD, PhD
Case Discussion published on March 17, 2016

MediCom Worldwide, Inc. Links

ManagingAML.com | ManagingMyeloma.com | ManagingMDS.com | ManagingMPN.com | PracticalOncologist.com | PracticalHematologist.com | ManagingCVD.com | ManagingSCD.com | MediComWorldwide.com

©2025 MediCom Worldwide, Inc. All rights reserved

  • Privacy, Terms, and Conditions
  • Contact Us